The Institute for Clinical and Economic Review (ICER) on Friday released a Final Condition Update report and Report-at-a-Glance on targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis.
ICER first reviewed treatments for plaque psoriasis in 2016. This update incorporates new clinical data and cost information for previously reviewed therapies, and includes analyses of more recently approved medications guselkumab (Tremfya, Johnson & Johnson), tildrakizumab (Ilumya, Sun Pharma/Merck), and certolizumab pegol (Cimzia, UCB), as well as risankizumab (AbbVie), which is currently being reviewed by the FDA.
ICER’s condition update report was reviewed at a July 2018 public meeting of the New England Comparative Effectiveness Public Advisory Council (New England CEPAC), one of ICER’s three independent evidence appraisal committees. During the meeting, the New England CEPAC votedthat, compared to TNFα inhibitors, both guselkumab and risankizumab offer a superior net health benefit based on currently available evidence.
The Council further voted that evidence was not adequate to show a net health benefit of tildrakizumab compared to TNFα inhibitors, or of the TNFα inhibitor certolizumab pegol over the other subcutaneously-administered TNFα inhibitors (adalimumab and etanercept).
“Similar to the findings of our 2016 report, we again found that many targeted therapies offer benefit over non-targeted therapies, and we are able to further clarify which agents may be most effective,” ICER CSO Dan Ollendorf said in a statement.
To read the full press release on ICER’s website, click here.
